Asset
CUDC-101
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00728793 | phase1 | completed | 2008-08-01 | 2010-04-01 | Curis, Inc. | A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors |
| NCT01171924 | phase1 | completed | 2010-07-01 | 2011-10-01 | Curis, Inc. | A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors |
| NCT01384799 | phase1 | completed | 2011-11-01 | 2013-09-01 | Curis, Inc. | Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer |
| NCT01702285 | phase1 | terminated | 2012-09-01 | 2012-12-01 | Curis, Inc. | Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients |
FDA applications (0)
This company has no applications containing this asset.